Pareto publishes research report setting price target of SEK 25 per share as new analyst assumes coverage
Hørsholm, Denmark, September 22, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has published a new research report on ExpreS2ion in September in which a new analyst, Marietta Miemietz, assumes coverage of the Company.“The pipeline is progressing at a rapid pace. Bavarian Nordic commenced recruitment into the phase III trial for the COVID-19 vaccine ABNCoV2 earlier this month and aims for launches in the EU & US in 2023. In mid-2023, the company expects to finish pre-clinical work on the HER2-targeted breast